{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:59:53Z","timestamp":1789750793833,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04847-w","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:16:55Z","timestamp":1777259815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis"],"prefix":"10.1186","volume":"26","author":[{"given":"Mustafa","family":"Mohamedrashed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiumaeswar","family":"Yogakanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leya","family":"Nedumannil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng Calvin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleiman","family":"Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9149-3589","authenticated-orcid":false,"given":"Mayur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"4847_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","volume":"4","author":"LC Dinesen","year":"2010","unstructured":"Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis Oct. 2010;4(4):431\u20137. https:\/\/doi.org\/10.1016\/j.crohns.2010.02.001.","journal-title":"J Crohns Colitis Oct"},{"issue":"4947","key":"4847_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"29","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J Oct. 1955;29(4947):1041\u20138. https:\/\/doi.org\/10.1136\/bmj.2.4947.1041.","journal-title":"Br Med J Oct"},{"issue":"1","key":"4847_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Jan. 2007;5(1):103\u201310. https:\/\/doi.org\/10.1016\/j.cgh.2006.09.033.","journal-title":"Clin Gastroenterol Hepatol Jan"},{"issue":"10","key":"4847_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","volume":"40","author":"A Aratari","year":"2008","unstructured":"Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis Oct. 2008;40(10):821\u20136. https:\/\/doi.org\/10.1016\/j.dld.2008.03.014.","journal-title":"Dig Liver Dis Oct"},{"issue":"4","key":"4847_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640620977405","volume":"9","author":"S Festa","year":"2021","unstructured":"Festa S, Scribano ML, Pugliese D, et al. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United Eur Gastroenterol J May. 2021;9(4):507\u201316. https:\/\/doi.org\/10.1177\/2050640620977405.","journal-title":"United Eur Gastroenterol J May"},{"issue":"11","key":"4847_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","volume":"9","author":"MC Choy","year":"2024","unstructured":"Choy MC, Li Wai Suen CFD, Con D, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol Nov. 2024;9(11):981\u201396. https:\/\/doi.org\/10.1016\/S2468-1253(24)00200-0.","journal-title":"Lancet Gastroenterol Hepatol Nov"},{"issue":"6","key":"4847_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut Jun. 1996;38(6):905\u201310. https:\/\/doi.org\/10.1136\/gut.38.6.905.","journal-title":"Gut Jun"},{"issue":"3","key":"4847_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/apt.12375","volume":"38","author":"A Croft","year":"2013","unstructured":"Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther Aug. 2013;38(3):294\u2013302. https:\/\/doi.org\/10.1111\/apt.12375.","journal-title":"Aliment Pharmacol Ther Aug"},{"issue":"8","key":"4847_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.crohns.2014.01.006","volume":"8","author":"R Monterubbianesi","year":"2014","unstructured":"Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis Aug. 2014;8(8):852\u20138. https:\/\/doi.org\/10.1016\/j.crohns.2014.01.006.","journal-title":"J Crohns Colitis Aug"},{"issue":"3","key":"4847_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.20524\/aog.2021.0584","volume":"34","author":"ML Grazie","year":"2021","unstructured":"Grazie ML, Bagnoli S, Dragoni G, et al. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol. 2021;34(3):370\u20137. https:\/\/doi.org\/10.20524\/aog.2021.0584.","journal-title":"Ann Gastroenterol"},{"key":"4847_CR11","doi-asserted-by":"publisher","first-page":"3162595","DOI":"10.1155\/2016\/3162595","volume":"2016","author":"K Endo","year":"2016","unstructured":"Endo K, Onodera M, Shiga H, et al. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. https:\/\/doi.org\/10.1155\/2016\/3162595.","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"4847_CR12","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1007\/s10620-022-07490-z","volume":"67","author":"A Caplan","year":"2022","unstructured":"Caplan A, McConnell R, Velayos F, Mahadevan U, Lewin S. Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis. Dig Dis Sci Dec. 2022;67(12):5455\u201361. https:\/\/doi.org\/10.1007\/s10620-022-07490-z.","journal-title":"Dig Dis Sci Dec"},{"issue":"7","key":"4847_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/jgh3.12933","volume":"7","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, Lo SW, Cheong R, et al. Factors associated with long-term healthcare expense and steroid exposure in patients admitted with acute severe ulcerative colitis. JGH Open Jul. 2023;7(7):482\u20136. https:\/\/doi.org\/10.1002\/jgh3.12933.","journal-title":"JGH Open Jul"},{"key":"4847_CR14","doi-asserted-by":"publisher","first-page":"204062231982559","DOI":"10.1177\/2040622319825595","volume":"10","author":"A Vasudevan","year":"2019","unstructured":"Vasudevan A, Arachchi A, Scanlon C, Greenhalgh J, Van Langenberg DR. A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy. Ther Adv Chronic Dis. 2019;10:2040622319825595. https:\/\/doi.org\/10.1177\/2040622319825595.","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"4847_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol May. 2024;9(5):415\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol May"},{"issue":"1","key":"4847_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol Sep. 2016;1(1):15\u201324. https:\/\/doi.org\/10.1016\/S2468-1253(16)30003-6.","journal-title":"Lancet Gastroenterol Hepatol Sep"},{"issue":"9857","key":"4847_CR17","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet Dec 1. 2012;380(9857):1909\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(12)61084-8.","journal-title":"Lancet Dec 1"},{"issue":"4","key":"4847_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ibd\/izaa088","volume":"15","author":"RK Grant","year":"2021","unstructured":"Grant RK, Jones GR, Plevris N, et al. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis Mar. 2021;15(4):451\u20137. https:\/\/doi.org\/10.1093\/ibd\/izaa088.","journal-title":"Inflamm Bowel Dis Mar"},{"issue":"3","key":"4847_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2022-327533","volume":"72","author":"A Adams","year":"2023","unstructured":"Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut Mar. 2023;72(3):433\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2022-327533.","journal-title":"Gut Mar"},{"issue":"7","key":"4847_CR20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.18190","volume":"60","author":"A Croft","year":"2024","unstructured":"Croft A, Okano S, Hartel G, et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther Oct. 2024;60(7):921\u201333. https:\/\/doi.org\/10.1111\/apt.18190.","journal-title":"Aliment Pharmacol Ther Oct"},{"issue":"6","key":"4847_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/apt.15456","volume":"50","author":"S Sebastian","year":"2019","unstructured":"Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther Sep. 2019;50(6):675\u201383. https:\/\/doi.org\/10.1111\/apt.15456.","journal-title":"Aliment Pharmacol Ther Sep"},{"issue":"2","key":"4847_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","volume":"13","author":"DJ Gibson","year":"2015","unstructured":"Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol Feb. 2015;13(2):330\u2013e3351. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.041.","journal-title":"Clin Gastroenterol Hepatol Feb"},{"issue":"3","key":"4847_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","volume":"9","author":"P Riviere","year":"2024","unstructured":"Riviere P, Li Wai Suen C, Chaparro M, De Cruz P, Spinelli A, Laharie D. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol Mar. 2024;9(3):251\u201362. https:\/\/doi.org\/10.1016\/S2468-1253(23)00313-8.","journal-title":"Lancet Gastroenterol Hepatol Mar"},{"issue":"1","key":"4847_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1071\/AH17031","volume":"43","author":"D Gleeson","year":"2019","unstructured":"Gleeson D, Townsend B, Lopert R, Lexchin J, Moir H. Financial costs associated with monopolies on biologic medicines in Australia. Aust Health Rev Feb. 2019;43(1):36\u201342. https:\/\/doi.org\/10.1071\/AH17031.","journal-title":"Aust Health Rev Feb"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04847-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:56:51Z","timestamp":1781229411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04847-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4847"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04847-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Northern health research committee (ID: 2024_non-HREC_29). Because of the retrospective nature of the study, the need for informed consent to participate was specifically waived by Northern health research committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"MG has served on the advisory board of Abbvie, Pfizer and Ferring, and has received speaker fees, research or travel grants from Abbvie, Celltrion, Dr Falk, Ferring, Fresenius Kabi, Janssen, Pfizer, and Takeda. RDL has received conference fees and travel support from Dr. Falk Pharma and Celltrion Healthcare and has received research funding from Celltrion Healthcare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"358"}}